Nexalin Technology Successfully Completes $5 Million Offering
Nexalin Technology, Inc. (NASDAQ: NXL; NXLIW) has recently announced the successful closing of its underwritten public offering, which involved the sale of 3,850,000 shares of common stock at a price of $1.30 per share. This offering garnered close to $5 million in gross proceeds for the company, reflecting a significant step for Nexalin in its commitment to advancing neurostimulation technology aimed at addressing mental health challenges.
Details of the Public Offering
The offering was managed solely by Maxim Group LLC, ensuring that the transaction was conducted smoothly and efficiently. This public offering followed an effective shelf registration statement filed earlier with the U.S. Securities and Exchange Commission (SEC), making the process streamlined and compliant with regulatory requirements. Nexalin's approach in this regard showcases their proactive strategy in capitalizing on the market to fund their innovative products.
Innovative Solutions for Mental Health
Nexalin is dedicated to developing leading-edge neurostimulation solutions designed to confront the global mental health epidemic. The company’s product line includes devices that are non-invasive and aim to provide relief to individuals experiencing mental health issues. Notably, their bioelectronic medical technology is engineered to target deep structures in the brain associated with these conditions, with the hope of enhancing patient outcomes without adverse side effects.
The Gen-2 Neurostimulation Device
Nexalin's latest Gen-2 15 milliamp neurostimulation device has gained approval in several countries, including China, Brazil, and Oman. This approval is a significant achievement that underscores Nexalin's commitment to expanding its reach in providing much-needed treatments for mental health disorders across various international markets. The company believes that their innovative waveforms will yield improved patient responses, addressing the pressing need for effective mental health therapies.
Path Forward for Nexalin Technology
The completion of this underwritten public offering places Nexalin in a stronger position to invest in further research and development of its neurostimulation technologies. As mental health issues continue to rise globally, Nexalin's focus on creating effective, non-invasive treatment options will be critical in contributing to solutions that address these challenges. The company is poised to leverage the funds acquired from this offering strategically and efficiently, fostering advancements in mental health therapies.
Investor Support and Communication
Nexalin values transparency and communication with its investors. For any inquiries, Crescendo Communications, representing Nexalin, is available via their contact number and email for direct engagement. This open line of communication reflects the company’s commitment to keeping stakeholders informed and engaged with the ongoing developments.
Frequently Asked Questions
What is the purpose of Nexalin's recent public offering?
The funds from the public offering aim to support the development and expansion of Nexalin's innovative neurostimulation technologies for mental health treatments.
Who managed Nexalin's public offering?
Maxim Group LLC served as the sole book-running manager for the public offering.
What types of products does Nexalin Technology offer?
Nexalin offers neurostimulation products designed to provide non-invasive treatment for various mental health issues, focusing on deep brain stimulation technology.
In which countries has the Gen-2 neurostimulation device been approved?
The Nexalin Gen-2 neurostimulation device has received approval in countries such as China, Brazil, and Oman.
How can investors contact Nexalin for further information?
Investors can contact Crescendo Communications, representing Nexalin, at (212) 671-1020 or via email at NXL@crescendo-ir.com.
